Source:http://linkedlifedata.com/resource/pubmed/id/20203671
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2010-3-5
|
pubmed:abstractText |
G protein-coupled receptors (GPCRs) and their downstream signaling cascades contribute to most physiological processes and a variety of human diseases. Isolating the effects of GPCR activation in an in vivo experimental setting is challenging as exogenous ligands have off-target effects and endogenous ligands constantly modulate the activity of native receptors. Highly specific designer drug-designer receptor complexes are a valuable tool for elucidating the effects of activating particular receptors and signaling pathways within selected cell types in vivo. In this study, we describe a generic protocol for the directed molecular evolution of designer receptors exclusively activated by designer drugs (DREADDs). First, the yeast system is validated with the template receptor. Second, a mutant library is generated by error-prone PCR. Third, the library is screened by drug-dependent yeast growth assays. Mutants exhibiting the desired properties are selected for further rounds of mutagenesis or for characterization in mammalian systems. In total, these steps should take 6-8 weeks of experimentation and should result in the evolution of a receptor to be activated by the chosen ligand. This protocol should help improve the experimental targeting of select cell populations.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/GM008719,
http://linkedlifedata.com/resource/pubmed/grant/GM07040,
http://linkedlifedata.com/resource/pubmed/grant/MH061887,
http://linkedlifedata.com/resource/pubmed/grant/MH082441,
http://linkedlifedata.com/resource/pubmed/grant/MH087074,
http://linkedlifedata.com/resource/pubmed/grant/R01 DA017204-07,
http://linkedlifedata.com/resource/pubmed/grant/U19 MH082441-030001,
http://linkedlifedata.com/resource/pubmed/grant/U19 MH082441-03S1,
http://linkedlifedata.com/resource/pubmed/grant/U19 MH082441-04,
http://linkedlifedata.com/resource/pubmed/grant/U19 MH082441-040001,
http://linkedlifedata.com/resource/pubmed/grant/U19 MH082441-05
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1750-2799
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
561-73
|
pubmed:dateRevised |
2011-2-14
|
pubmed:meshHeading |
pubmed-meshheading:20203671-Designer Drugs,
pubmed-meshheading:20203671-Directed Molecular Evolution,
pubmed-meshheading:20203671-Drug Design,
pubmed-meshheading:20203671-Humans,
pubmed-meshheading:20203671-Ligands,
pubmed-meshheading:20203671-Pheromones,
pubmed-meshheading:20203671-Protein Engineering,
pubmed-meshheading:20203671-Receptors, G-Protein-Coupled,
pubmed-meshheading:20203671-Saccharomyces cerevisiae,
pubmed-meshheading:20203671-Signal Transduction
|
pubmed:year |
2010
|
pubmed:articleTitle |
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs.
|
pubmed:affiliation |
Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|